NCT07344818

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma

Detailed description

In this study, anti-CD19 and anti-CD20 dual target CAR-T cell therapy will be explored for patients with relapsed/refractory aggressive B-cell lymphoma. In this study, the 3+3 dose climbing mode will be used to explore the safety and efficacy of dual-target CAR-T cells in r/r B-NHL therapy at different doses. The RP2D dose will be determined after the relevant data is summarized。

Conditions

• R/R Aggressive B-cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T cell therapy	autologous CD19+CD20 dual CAR-T cells, single injection

Timeline

• Start date: 2026-01-07
• Primary completion: 2027-03-31
• Completion: 2028-05-31
• First posted: 2026-01-15
• Last updated: 2026-01-15

Locations

1 site across 1 country: China